Force T, Kyriakis J M, Avruch J, Bonventre J V
Medical Services, Massachusetts General Hospital, Boston 02114.
J Biol Chem. 1991 Apr 5;266(10):6650-6.
Protein tyrosine phosphorylation has not been considered to be important for cellular activation by phospholipase C-linked vasoactive peptides. We found that endothelin, angiotensin II, and vasopressin (AVP), peptides that signal via phospholipase C activation, rapidly enhanced tyrosine phosphorylation of proteins of approximate molecular mass 225, 190, 135, 120, and 70 kDa in rat renal mesangial cells. The phosphorylated proteins were cytosolic or membrane-associated, and none were integral to the membrane, suggesting that the peptide receptors are not phosphorylated on tyrosine. Epidermal growth factor (EGF), which does not activate phospholipase C in these cells, induced the tyrosine phosphorylation of its own 175-kDa receptor, in addition to five proteins of identical molecular mass to those phosphorylated in response to endothelin, AVP, and angiotensin II. This suggests that in mesangial cells there is a common signaling pathway for phospholipase C-coupled agonists and agonists classically assumed to signal via receptor tyrosine kinase pathways, such as EGF. The phorbol ester, phorbol 12-myristate 13-acetate, and the synthetic diacylglycerol, oleoyl acetylglycerol, stimulated the tyrosine phosphorylation of proteins identical to those phosphorylated by the phospholipase C-linked peptides, suggesting that protein kinase C (PKC) activation is sufficient to active tyrosine phosphorylation. However, the PKC inhibitor, staurosporine, and down-regulation of PKC activity by prolonged exposure to phorbol esters completely inhibited tyrosine phosphorylation in response to PMA but not to endothelin, AVP, or EGF. In conclusion, endothelin, angiotensin II, and AVP enhances protein tyrosine phosphorylation via at least two pathways, PKC-dependent and PKC-independent. Although activation of PKC may be sufficient to enhance protein tyrosine phosphorylation, PKC is not necessary and may not be the primary route by which these agents act. At least one of these pathways is shared with the growth factor EGF, suggesting not only common intermediates in the signaling pathways for growth factors and vasoactive peptides but also perhaps common cellular tyrosine kinases which phosphorylate these intermediates.
蛋白酪氨酸磷酸化一直未被认为在磷脂酶C偶联的血管活性肽介导的细胞激活过程中起重要作用。我们发现,内皮素、血管紧张素II和血管加压素(AVP),这些通过激活磷脂酶C来传递信号的肽类,能迅速增强大鼠肾系膜细胞中分子量约为225、190、135、120和70 kDa的蛋白质的酪氨酸磷酸化。磷酸化的蛋白质存在于细胞质或与膜相关,没有一个是膜整合蛋白,这表明肽受体的酪氨酸没有被磷酸化。表皮生长因子(EGF)在这些细胞中不激活磷脂酶C,它除了能诱导自身175 kDa受体的酪氨酸磷酸化外,还能诱导另外五种与内皮素、AVP和血管紧张素II刺激后磷酸化的蛋白质分子量相同的蛋白质发生酪氨酸磷酸化。这表明在系膜细胞中,磷脂酶C偶联的激动剂和传统上认为通过受体酪氨酸激酶途径传递信号的激动剂(如EGF)存在共同的信号通路。佛波酯、佛波醇12 -肉豆蔻酸酯13 -乙酸酯和合成二酰基甘油油酰乙酰甘油,能刺激与磷脂酶C偶联肽磷酸化的蛋白质相同的蛋白质发生酪氨酸磷酸化,这表明蛋白激酶C(PKC)的激活足以激活酪氨酸磷酸化。然而,PKC抑制剂星形孢菌素以及通过长时间暴露于佛波酯使PKC活性下调,完全抑制了对佛波酯肉豆蔻酸酯(PMA)响应的酪氨酸磷酸化,但对内皮素、AVP或EGF则没有影响。总之,内皮素、血管紧张素II和AVP通过至少两条途径增强蛋白酪氨酸磷酸化,即PKC依赖性途径和PKC非依赖性途径。虽然PKC的激活可能足以增强蛋白酪氨酸磷酸化,但PKC并非必需,也可能不是这些因子发挥作用的主要途径。这些途径中至少有一条与生长因子EGF共享,这不仅表明生长因子和血管活性肽的信号通路中有共同的中间体,还可能表明存在共同的细胞酪氨酸激酶对这些中间体进行磷酸化。